These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 17530016

  • 1. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions.
    Bonavida B.
    Oncogene; 2007 May 28; 26(25):3629-36. PubMed ID: 17530016
    [Abstract] [Full Text] [Related]

  • 2. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
    Jazirehi AR, Bonavida B.
    Oncogene; 2005 Mar 24; 24(13):2121-43. PubMed ID: 15789036
    [Abstract] [Full Text] [Related]

  • 3. Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions.
    Vega MI, Huerta-Yepez S, Martinez-Paniagua M, Martinez-Miguel B, Hernandez-Pando R, González-Bonilla CR, Chinn P, Hanna N, Hariharan K, Jazirehi AR, Bonavida B.
    Clin Cancer Res; 2009 Nov 01; 15(21):6582-94. PubMed ID: 19861448
    [Abstract] [Full Text] [Related]

  • 4. Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's lymphoma.
    Bonavida B, Vega MI.
    Drug Resist Updat; 2005 Nov 01; 8(1-2):27-41. PubMed ID: 15939340
    [Abstract] [Full Text] [Related]

  • 5. Development of rituximab-resistant B-NHL clones: an in vitro model for studying tumor resistance to monoclonal antibody-mediated immunotherapy.
    Jazirehi AR, Bonavida B.
    Methods Mol Biol; 2011 Nov 01; 731():407-19. PubMed ID: 21516425
    [Abstract] [Full Text] [Related]

  • 6. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.
    Jazirehi AR, Vega MI, Bonavida B.
    Cancer Res; 2007 Feb 01; 67(3):1270-81. PubMed ID: 17283164
    [Abstract] [Full Text] [Related]

  • 7. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis.
    Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B.
    Cancer Res; 2005 Jan 01; 65(1):264-76. PubMed ID: 15665303
    [Abstract] [Full Text] [Related]

  • 8. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance.
    Vega MI, Huerta-Yepaz S, Garban H, Jazirehi A, Emmanouilides C, Bonavida B.
    Oncogene; 2004 Apr 29; 23(20):3530-40. PubMed ID: 15077178
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
    Jazirehi AR, Vega MI, Chatterjee D, Goodglick L, Bonavida B.
    Cancer Res; 2004 Oct 01; 64(19):7117-26. PubMed ID: 15466208
    [Abstract] [Full Text] [Related]

  • 10. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.
    Treon SP, Mitsiades C, Mitsiades N, Young G, Doss D, Schlossman R, Anderson KC.
    J Immunother; 2001 Oct 01; 24(3):263-71. PubMed ID: 11394505
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis.
    Alas S, Emmanouilides C, Bonavida B.
    Clin Cancer Res; 2001 Mar 01; 7(3):709-23. PubMed ID: 11297268
    [Abstract] [Full Text] [Related]

  • 12. Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis.
    Zhao WL, Wang L, Liu YH, Yan JS, Leboeuf C, Liu YY, Wu WL, Janin A, Chen Z, Chen SJ.
    Exp Hematol; 2007 Dec 01; 35(12):1801-11. PubMed ID: 17681667
    [Abstract] [Full Text] [Related]

  • 13. Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis.
    Vega MI, Huerta-Yepez S, Jazirehi AR, Garban H, Bonavida B.
    Oncogene; 2005 Dec 08; 24(55):8114-27. PubMed ID: 16103877
    [Abstract] [Full Text] [Related]

  • 14. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy.
    Zhou X, Hu W, Qin X.
    Oncologist; 2008 Sep 08; 13(9):954-66. PubMed ID: 18779537
    [Abstract] [Full Text] [Related]

  • 15. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.
    Maddipatla S, Hernandez-Ilizaliturri FJ, Knight J, Czuczman MS.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4556-64. PubMed ID: 17671142
    [Abstract] [Full Text] [Related]

  • 16. Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab).
    Nishida M, Usuda S, Okabe M, Miyakoda H, Komatsu M, Hanaoka H, Teshigawara K, Niwa O.
    Int J Oncol; 2007 Jul 01; 31(1):29-40. PubMed ID: 17549402
    [Abstract] [Full Text] [Related]

  • 17. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression.
    Olejniczak SH, Hernandez-Ilizaliturri FJ, Clements JL, Czuczman MS.
    Clin Cancer Res; 2008 Mar 01; 14(5):1550-60. PubMed ID: 18316580
    [Abstract] [Full Text] [Related]

  • 18. Down-regulation of mcl-1 by small interfering RNA sensitizes resistant melanoma cells to fas-mediated apoptosis.
    Chetoui N, Sylla K, Gagnon-Houde JV, Alcaide-Loridan C, Charron D, Al-Daccak R, Aoudjit F.
    Mol Cancer Res; 2008 Jan 01; 6(1):42-52. PubMed ID: 18234961
    [Abstract] [Full Text] [Related]

  • 19. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R, Hagenbeek A.
    Eur J Haematol Suppl; 2007 Jan 01; (67):5-14. PubMed ID: 17206982
    [Abstract] [Full Text] [Related]

  • 20. What signals are generated by anti-CD20 antibody therapy?
    Bonavida B.
    Curr Hematol Malig Rep; 2006 Dec 01; 1(4):205-13. PubMed ID: 20425315
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.